Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer

Farid, Mohamad; Chowbay, Balram; Chen, Xiangai; Tan, Sze Huey; Subbaiya, Ramasamy; Koo, Wen Hsin; Toh, Han Chong; Choo, Su Pin; Ong, Simon Yew Kuang

doi:10.1007/s00280-012-1895-x

Cited by 7 publications

(2 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With regard to the lack of requirement for a CV port and infusion pump, CapeOX plus bevacizumab therapy was an option for first-line therapy in the present case. However, hand-foot syndrome as a side effect of capecitabine and peripheral neuropathy as a side effect of oxaliplatin are frequently observed, and management of these side effects is essential (18,19). In the present case, the patient was hesitant to be treated with oxaliplatin and capecitabine due to these side effects.…”

Section: Discussionmentioning

confidence: 99%

Complete response of lung metastases from rectal cancer to combination first-line therapy of S-1 and irinotecan plus bevacizumab: A case report and review of the literature

et al. 2014

View full text Add to dashboard Cite

This report presents the case of a 72-year-old male who had undergone abdominoperineal resection following a diagnosis of lower rectal cancer with multiple lung metastases. Pathologically, the resected specimen exhibited advanced rectal cancer with regional lymphoid metastases and was classified as stage IV disease. S-1 and irinotecan (IRIS) plus bevacizumab combination therapy was used to treat the lung metastases following the surgery. S-1 (100 mg/body) was administered orally on days 1–14 of a 28-day cycle, and irinotecan (125 mg/m2) and bevacizumab (7.5 mg/kg) were administered by intravenous infusion on days 1 and 15. Computed tomography revealed a marked decrease in the size of the metastases following three therapeutic courses, and no lung metastases or new lesions were detected following nine therapeutic courses. The response was declared clinically complete. The patient refused additional treatment following nine therapeutic courses, and there was no recurrence 36 months after the final course of therapy. This case demonstrates the efficacy of IRIS plus bevacizumab as a first-line combination therapy against lung metastases of rectal cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Complete response of lung metastases from rectal cancer to combination first-line therapy of S-1 and irinotecan plus bevacizumab: A case report and review of the literature

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Our enzyme activity data, which were collected in accordance with the policy of the local ethics committee, were compared with data from the literature [1,2,3,4,5]. In total, 128 subjects at 12 different dose levels were included.…”

Section: Methodsmentioning

confidence: 99%

A Simple Method for Comparing Enzymatic Capecitabine Activation in Various Mono- and Combination Chemotherapies

Sahmanovic¹,

Schreiber²,

Baroian³

et al. 2015

Pharmacology

View full text Add to dashboard Cite

Before being able to develop a pharmacodynamic effect, a number of drugs have to be activated by enzymes, which are known to be potentially influenced by manifold factors, leading to a possible alteration of their activity behaviour. Based on capecitabine, we report a simple and rapid method for the estimation and comparison of the so-called ‘apparent enzyme activity' (R), not only intra- (different dose levels) but also inter-schedule, to contribute to therapeutic success. Dividing the area under the curve (AUC) of the product by the AUC of the precursor generates a factor which indicates the apparent activity of the enzyme involved in the biotransformation of a compound. Our own data as well as data from the literature was used to calculate those R levels revealing that the formation of 5′-DFUR - the immediate precursor of 5-fluorouracil - was not affected by concomitant medication within the dosing range investigated. Calculated hypothetical means of R for carboxylesterase (1.49 ± 0.66) and for cytidine deaminase (1.17 ± 0.65) were obtained. Additionally, it is important to note that the method described in this report is of general use and not limited to chemotherapeutic agents, as soon as enzymes are involved in drug activation.

show abstract

Genomic Targets and Dose‐Finding

2018

Sample Sizes for Clinical, Laboratory and Epidemiology Studies

View full text Add to dashboard Cite

Phase I pharmacokinetic study of chronomodulated dose-intensified combination of capecitabine and oxaliplatin (XELOX) in metastatic colorectal cancer

Abstract: Chronomodulated dose-intensified XELOX facilitates delivery of dose-intense treatment in mCRC with a favorable therapeutic index that is promising.

Cited by 7 publications

References 30 publications

Complete response of lung metastases from rectal cancer to combination first-line therapy of S-1 and irinotecan plus bevacizumab: A case report and review of the literature

Complete response of lung metastases from rectal cancer to combination first-line therapy of S-1 and irinotecan plus bevacizumab: A case report and review of the literature

A Simple Method for Comparing Enzymatic Capecitabine Activation in Various Mono- and Combination Chemotherapies

Genomic Targets and Dose‐Finding

Contact Info

Product

Resources

About